Global 3D Cell Culture Market Seeks Prosperous Horizon: Double-Digit Growth Expected by 2027

 

The need for organ transplants and tissue engineering combined with developments in scaffold-free technology, a rise in investments and research and development (R&D) funding for cell-based studies, growing efforts to develop potential alternatives to animal-based testing, and the rising incidence of chronic diseases are some of the major factors propelling the growth of the global 3D cell culture market.

3D cell culture is an important approach in cell biology and tissue engineering because it includes cultivating and analyzing cells in a three-dimensional environment that mimics the circumstances present in the human body. It has several advantages, such as the capacity to recreate in vivo settings, allow the creation of complex multicellular structures, and give realistic drug testing situations. Scaffold-based technologies employing materials such as hydrogels are employed for 3D cell culturing. Its uses include cancer research, tissue engineering, and medication development, resulting in more precise drug effects evaluations. However, it has several drawbacks, such as greater complexity, the requirement for specialized equipment and knowledge, and potentially higher costs as compared to 2D cell culture. Bioprinting is often integrated into 3D cell culture, enabling precise cell and biomaterial placement, while organoids, a specific type of 3D cell culture, have gained prominence in disease modeling and drug testing.

Meeting the Demands of Modern Research by Advancing 3D Cell Culture Market Techniques

Due to a number of compelling considerations, 3D cell culture is gaining popularity in cell biology and tissue engineering. The most pressing need is for more physiologically appropriate cell culture models. Traditional 2D cultures frequently fail to effectively recreate in vivo settings, resulting in erroneous results in drug testing, disease modeling, and toxicity investigations. Another driving reason is improved drug testing, since 3D cell culture provides a superior platform for predicting drug behavior within the human body, possibly lowering drug development costs and timeframes.

3D cell culture considerably helps tissue engineering, allowing for the production of complex tissues and organs for transplantation and study. When compared to typical monolayer cultures, 3D cell cultures provide more realistic tumor development and behavior modeling in cancer research. Furthermore, 3D culture techniques that facilitate stem cell differentiation and proliferation assist stem cell research.

For instance,

·        In June 2023, Vertex Pharmaceuticals Incorporated and Lonza unveiled a strategic partnership aimed at facilitating the production of Vertex's range of prospective stem cell-derived, fully specialized insulin-producing islet cell therapies designed for individuals with Type 1 Diabetes (T1D). The collaboration primarily focuses on the VX-880 and VX-264 programs, both of which are presently undergoing clinical trials

·        In October 2022, Corning Incorporated expanded its 3D cell culture offerings by introducing the Elplasia12K flask to its product line. This flask is specifically designed to facilitate spheroid culture, a method commonly utilized in cancer research and the advancement of therapeutic treatments.

With the emergence of personalized medicine, it is now possible to create 3D cell culture models from a patient's cells for tailored medication testing and treatment programs. Biomaterial innovations, such as hydrogels and scaffolds, make it easier to create 3D cell growth settings. Researchers' interdisciplinary collaboration accelerates the development of 3D cell culture techniques.

For instance,

·        In June 2023, Bristol Myers Squibb received approval from the U.S. Food and Drug Administration (FDA) for commercial production at their recently established cell therapy manufacturing facility in Devens, Massachusetts. This facility is a vital part of Bristol Myers Squibb's growing global network for producing cell therapies, ensuring a consistent supply of these treatments in the long term, and delivering these therapies to patients worldwide who have unmet medical needs

·        In March 2021, Thermo Fisher Scientific introduced the Gibco Human Plasma-like Medium (HPLM), marking the debut of the first cell culture medium that replicates the metabolic characteristics of human plasma. This innovative medium is specifically created to offer researchers a more authentic perspective on cell growth as it occurs within the human body.

North America Accounts for the Largest Share of the Global 3D Cell Culture Market

The scale of the market varies by area, with richer countries often having more established offerings. North America is in first place, followed by Europe and other areas. Advanced healthcare infrastructure, the presence of key players, supportive regulatory frameworks, government support for 3D culture model development, and an increase in R&D activities by the number of research institutes and universities are all expected to drive the market in North America.

The Asia Pacific region is expected to grow the fastest during the forecast period, owing to an increase in chronic diseases, a thriving biotechnology sector, increased company investments due to lower manufacturing costs, rising demand for cellular therapies, and robust research potential.

Competitive Landscape Analysis of the 3D Cell Culture Market

Some prominent players competing in the global 3D cell culture market include Thermo Fisher Scientific, Inc., Merck KGaA, Lonza, Corning Incorporated, Avantor, Inc., PromoCell GmbH, Tecan Trading AG, REPROCELL Inc., CN Bio Innovations Ltd, and Lena Biosciences among others.

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the 3D Cell Culture Market

Players operating in this market are adopting both organic and inorganic growth strategies such as enhancing manufacturing capabilities, collaborations, and acquisitions to garner market share. For instance,

·        In July 2023, Merck announced a €23 million investment to expand its cell culture media production in Kansas, USA. The expansion includes the addition of 9,100 square meters of lab space and improved production capabilities

·        In November 2022, FUJIFILM Corporation announced a substantial investment of $188 million to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The facility will encompass more than 250,000 square feet on 64 acres to meet the growing market demand and focus on the production of animal component-free, dry powder, and liquid media to support bioproduction and advanced therapies, contributing to the advancement of life science and healthcare research and development.

The market is expected to expand further as a result of rising demand for personalized medicine, increased adoption of 3D cell cultures in cancer research, the need for more accurate and physiologically relevant models in various fields of research and application, technological innovations, and aggressive organic and inorganic growth strategies employed by the players.

Get Detailed Insights on the 3D Cell Culture Market @ https://meditechinsights.com/3d-cell-culture-market/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com